Journal publishes data on use of Valortim to fight anthrax

PharmAthene, Inc., recently announced that a major peer-reviewed journal has published data supporting the potential use of Valortim, a fully human monoclonal antibody, as both a post-exposure prophylaxis and a treatment for anthrax infection.

The December issue of Clinical and Vaccine Immunology, the journal of the American Society for Microbiology, published the results of PharmAthene’s Phase I clinical study, which was conducted to assess the safety and tolerability of Valortim.

"There is a strong need for additional therapeutic options for inhalational anthrax disease as current therapies, specifically antibiotics and aggressive supportive care, are not optimally effective in individuals with active, symptomatic anthrax infection,” Dr. Thomas Fuerst, the executive vice-president of PharmAthene, said. “Anti-toxin therapies like Valortim could potentially provide important protection in the event of a bioterrorism attack with anthrax.”

Preclinical studies showed that Valortim was capable of protecting rabbits and non-human primates against the lethal effects of anthrax infection when administered at the time of exposure. They also showed that drug capable of improving survival as late as 48 hours post-exposure.

"Our Phase I results demonstrate that a single dose of Valortim can provide levels of antibodies in humans that correspond to protective levels in animal models and is well tolerated,” Fuerst said. “Based on the accumulating human safety and animal efficacy data for Valortim, we believe that it could represent an important addition to the nation's anthrax armamentarium."

Organizations in this story

American Society for Microbiology 1752 N St NW Washington, DC 20036

Get notified the next time we write about American Society for Microbiology!